ERNA - Ernexa Therapeutics Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ERNA

ERNEXA THERAPEUTICS INC.

NASDAQ

$4.31

▼ DOWN 4.86% (-0.22)

KEY STATISTICS

Market Cap$1.35 M

52w High$71.50

52w Low$3.18

Dividend Yield—

Frequency—

P/E-0.54

Volume46.69K

Shares Out.314.12K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Sanjeev Luther

COMPENSATION 2026

Salary$550,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$14,000

Total$888,813

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 29, 1991

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 6, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2026-05-04	Reverse	1:25
2025-06-12	Reverse	1:15
2022-10-17	Reverse	1:20
2021-03-26	Reverse	1:2
2016-06-17	Reverse	1:50

PRICE

$4.31 ▼ DOWN 4.86% (−$0.22)

OVERLAYS

About Ernexa Therapeutics Inc.

https://www.ernexatx.com ↗

Ernexa Therapeutics Inc., founded in 2018 in Cambridge, MA, develops allogenic iMSC therapies for solid tumors and autoimmune diseases, with lead products ERNA-101 for ovarian cancer and ERNA-102 for rheumatoid arthritis.

INDUSTRY

Biotechnology

A PRODUCT ERNEXA THERAPEUTICS INC. IS KNOWN FOR

ERNA-101

ERNA-101 is a preclinical allogeneic iMSC therapy that activates the immune system to target cancer, initially focusing on ovarian cancer, marking the company's new strategic lead candidate toward clinical trials.